News

Medicare Advantage usage trends reveal slight declines in 2023, highlighting critical insights for policymakers amid rising ...
Eli Lilly's stock is lagging the S&P 500 since April, potentially allowing a catch-up trade if results impress. Medicare may ...
Health and Human Services Secretary Robert F. Kennedy Jr said that President Donald Trump calls him up “three or four times a week” to hound him with the same question. At such a critical moment in US ...
GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...
Legislative efforts and a Trump administration initiative could lead in the near future to Medicare beneficiary access to ...
Relief is coming for more than 5 million Medicare beneficiaries who rely on expensive prescription medications.
UBS downgraded its rating of Novo to "neutral" from "buy" and lowered its 12-month price target to 340 Danish krone from 600 Danish krone. Copenhagen-listed shares in Novo, which have slumped by more ...
The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...
Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.
Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...
The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...
A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...